Facebook
X
LinkedIn
Forward29th University of Chicago Comprehensive Cancer Center Developmental Therapeutics Symposium
Chicago, IL US
May 8, 2026
Stay at the forefront of oncology innovation!
This symposium brings clinicians a dynamic, evidence-based exploration of the most promising investigational agents shaping the future of cancer care. Through expert analysis of completed studies and in-depth discussion of ongoing clinical trials, participants will gain a clear understanding of the scientific rationale, emerging data, and real-world implications of novel therapies for patients with advanced cancer, including when and how leading agents are being introduced into the frontline setting.
Designed for practicing oncologists and oncology professionals, this activity equips you to confidently integrate new treatments into patient care, strengthen your role in current and future clinical trials, and lead with authority in an increasingly complex therapeutic landscape. By emphasizing the practical applications of precision medicine, this program empowers you to translate cutting-edge research into improved patient outcomes for those with cancer.
For more information, visit the symposium website!
Target Audience
This activity is designed for physicians and other healthcare professionals who diagnose, screen, and treat patients with cancer.
Learning Objectives
After this activity, participants will be able to:
- Summarize current approaches to pre- and post-FDA approval dosing and scheduling of emerging anti-cancer agents to optimize therapeutic decision-making for patients with cancer.
- Describe the mechanisms and clinical effects of novel immunotherapeutics, including checkpoint inhibitors, bispecific antibodies, and cellular therapies, to inform evidence-based treatment planning and improve patient outcomes.
- Apply principles of molecular oncology to select systemic therapies that target genomic alterations, enhancing precision medicine-based patient management.
- Analyze the developmental pathways and clinical rationale for antibody-drug conjugates in solid and hematologic malignancies to support evidence-informed therapeutic choices.
- Evaluate patient suitability for ongoing and upcoming clinical trials by interpreting next-generation sequencing results and eligibility criteria to advance equitable and appropriate clinical trial enrollment strategies.
- Integrate pharmacologic, biologic, and imaging-based data through structured interpretation to construct evidence-informed considerations for the use of novel anti-cancer agents to strengthen early-phase therapeutic decision-making.
You may also be interested in
David Rubenstein Forum at the University of Chicago
1201 E 60th St
Chicago, IL
60637
United States
HYBRID ACTIVITY
Learners can participate in person or virtually. For more information, visit the symposium website or contact Meeting Achievements via email.
DAVID RUBENSTEIN FORUM
The David Rubenstein Forum combines a variety of spaces, both formal and informal, large and small, calm and animated, focused and diffuse, scheduled and spontaneous. Its ten-story tower features vibrant and distinct “neighborhoods.” For example, the third and fourth floors are home to Friedman Hall, a 285-seat auditorium optimized for spoken word, including keynote speeches, invited-speaker addresses, and select performances; these floors and other neighborhoods are connected by a two-story lounge. Meeting rooms on the eighth and ninth floors feature premium furnishings, finishes, and equipment, such as the Peter May Boardroom, a tiered meeting space that seats over 70. The Rubenstein Forum’s unique position on the Midway allows for expansive views toward the campus and surrounding communities as well as downtown Chicago and Lake Michigan.
VISITING CHICAGO
Discover why Condé Nast Traveler readers voted Chicago the Best Big City in the U.S. for a historic ninth year in a row. To help plan your stay in Chicago, visit Choose Chicago.
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact our office via email.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, the University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
UNIVERSITY OF CHICAGO COURSE DIRECTORS
Olatoyosi Odenike, MD
Professor of Medicine
Director, Leukemia Program
Professor of Medicine
Director, Leukemia Program
Gini Fleming, MD
Professor of Medicine
Medical Director, Gynecologic Oncology
For more information, visit the symposium website.
Professor of Medicine
Medical Director, Gynecologic Oncology
For more information, visit the symposium website.
Disclosure Declarations
As a provider accredited by the ACCME, the University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships before the start of the activity.
Additionally, the University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, the University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships before the start of the activity.
Additionally, the University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 5.25 contact hours.
American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other Participant Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please note: The credit claiming process will close 30 days after the activity ends. Requests to claim credit after 30 days may incur additional fees.
HOW TO REGISTER
Please log in or create an account to register. Once logged in, select the registration type that best suits you. For help, follow our 
registration guide.
registration guide.| IN-PERSON AND VIRTUAL FEES | |
| Profession Type | Fee |
| Physician | $50 |
| Healthcare Professional | $25 |
| Trainee | $25 |
| Industry | $350 |
| CANCELLATION POLICY: If you cancel your participation in this conference, your registration fee less a 50% administrative fee will be refunded when written notification is received by April 8, 2026. No refunds will be made after April 8, 2026. | |
HOW TO CLAIM CREDIT
At the end of the activity, the credit-claiming process will unlock. Return to this page and click on "Complete Activity" to proceed.
Please note: The credit claiming process will close 30 days after the activity ends. Requests to claim credit after 30 days may incur additional fees.
Please note: The credit claiming process will close 30 days after the activity ends. Requests to claim credit after 30 days may incur additional fees.
Please login or create an account to proceed.